Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 14/20 | 0.62 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 4/20 | 0.58 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.57 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.57 |
| ▸ | NSD2 | O96028 | 3/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.54 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230764 | 0.96 | TLR7 (0.58) | EHMT2DNMT3AKDM1ARCOR1APP | |
| SCHEMBL3775638 | 0.90 | SSTR5 (0.55) | EHMT2KDM1ARCOR1APPNSD2 | |
| SCHEMBL3775880 | 0.89 | SSTR5 (0.57) | EHMT2KDM1ARCOR1APPNSD2 | |
| SCHEMBL3774437 | 0.89 | EHMT2 (0.55) | EHMT2KDM1ARCOR1APPNSD2 | |
| SCHEMBL3779098 | 0.88 | EHMT2 (0.55) | EHMT2KDM1ARCOR1APPNSD2 | |
| SCHEMBL3772515 | 0.88 | EHMT2 (0.53) | EHMT2KDM1ARCOR1APPNSD2 | |
| SCHEMBL3776962 | 0.88 | SSTR5 (0.57) | EHMT2KDM1ARCOR1APPNSD2 | |
| SCHEMBL3781568 | 0.88 | SSTR5 (0.57) | EHMT2KDM1ARCOR1APPNSD2 | |
| SCHEMBL4234177 | 0.85 | EHMT2 (0.51) | EHMT2KDM1ARCOR1APPNSD2 | |
| SCHEMBL3781168 | 0.85 | EHMT2 (0.51) | EHMT2KDM1ARCOR1APPNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | EHMT2 4728/4885DNMT3A 4775/4885KDM1A 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.